Last month, Bayer AG opened the doors on a $335 million joint venture with Crispr Therapeutics to develop therapies using a new gene-editing tool. Later this year, rival Editas Medicine Inc. will move into larger digs as it, too, races ahead with a $200 million-plus effort to leverage the gene-editing tool into new drugs. The flurry belies the fact that the companies don’t actually know yet who owns the intellectual-property rights to the technology.http://www.wsj.com/articles/breakthrough-gene-technology-attracts-investors-amid-patent-dispute-1474567512